retatrutide phase 2 trial obesity nejm 2023 in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide Phase 2 NEJM Trial:
Description
High blood sugar levels can lead to problems in various parts of your body, especially your eyes, kidneys, and nerves
All information presented here is not meant as a substitute for or alternative to information from health care practitioners
Comparing intranasal retatrutide to other nasal peptides Intranasal retatrutide is not the first peptide to be explored through nasal delivery
Defer, G
The body may still be adapting to: Weight loss Appetite suppression Lower calorie intake Hydration changes Hormonal shifts However, severe or persistent fluctuations should not be ignored
